Grants

Exploring the Use of Artificial Intelligence (AI) Applications in ALK+ NSCLC (oncology | Italy)

The Exploring the Use of Artificial Intelligence (AI) Applications in ALK+ NSCLC research funding from Pfizer seeks to improve the quality of care or quality of healthcare services for patients with ALK+Non-Small Cell Lung Cancer (NSCLC) through the incorporation of AI applications and clinical tools. Applications are open to cancer researchers in Italy.

Applicants may apply for up to 90,000 EUR for 2 years (including up to 28% for institutional indirect costs/overheads).

Applications close on May 26, 2025.

The grant has closed. Sign-up for our content alerts to be updated when it re-opens.

Premium member content
login or subscribe to see the full content.
join
Scientify research logo

Let's keep in touch​